Devyser´s annual report 2025 has today been published on the company´s website.The report is available on: https://investors.devyser.com/en/reports-presentationsThe financial year covers…
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing (NGS) assay for genetic analysis of thalassemia and sickle cell disease (SCD) available…
“The fourth quarter confirmed the positive earnings trend that we have seen throughout the year. Operating profit amounted to SEK 18.0 million (-3.7) for the quarter and to SEK 10.1…
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has entered into an agreement relating to the acquisition of 100 percent of the shares in…
On Thursday February 12 at 9:00 a.m. CET, Devyser Diagnostics AB will host an online presentation of its Q4 2025 report (which will have been published earlier on February 12 at 07:30…
Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA sequencing and array-based technologies, to provide Illumina sequencing instruments and…
Devyser is proud to announce that the company has been awarded a tender by Oslo University Hospital for the supply of Devyser CFTR, the company’s advanced genetic testing kit designed for…
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a new tender in Marseille, France, valued up to SEK 9.5 million over a 48-month period.
This tender…
Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been granted approval as Class III In Vitro Diagnostic (IVD) medical devices by Health Canada.…
Devyser today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its final pricing determination for the company’s PrenatalDetect RHD test (CPT 0536U) at…
